The proposed changes to the Medicare Shared Savings Program could prevent the program from driving broad change to value-based care across the country, according to Katherine Schneider, MD, MPhil, FAAFP, president and CEO of Delaware Valley ACO.
The proposed changes to the Medicare Shared Savings Program could prevent the program from driving broad change to value-based care across the country, according to Katherine Schneider, MD, MPhil, FAAFP, president and CEO of Delaware Valley ACO.
Transcript
What is the greatest challenge you see with CMS’ proposed changes to the MSSP?
The Pathways to Success proposed rules changes have a couple of really major concerns, and I think the biggest one is really the impact not on folks like me, who’ve been in the program for 5 years, but it’s on those who are either new entrants or are considering getting in.
Two things. Number 1, the accelerated pace to taking downside risk, the proposal of it being 2 years is just not viable at all. Having gone through being in the program, and actually I was part of the demonstration project 10, 15 years ago that was the precursor, you don’t even know your first-year performance until after the time that you would have to commit to taking downside risk in year 3. That’s just not viable. Let alone have any cash flows. Certainly not viable from a responsible business due diligence perspective.
And the second is the attractiveness of coming in. The gain sharing proportion being reduced from 50% to 25%. I can say with absolute certainty that if those 2 rules had been in effect and with the lack of ability to do things like a Medicare Advantage plan can do in terms of benefit design, in terms of risk adjustment, there’s no way we would have gone into the program. And we’re one of the biggest ACOs in the country. And we committed to this model. And I personally believe that it’s capable of driving broad change across the country in a way that niche programs really can’t do.
So, my biggest concern is really that if we focus just on, “well, the program will just serve a couple of high-performing ACOs,” you’re going to have a great program that nobody is in. And that’s a real concern.
There are other smaller issues around operational things, like beneficiary notifications, going backwards on that. But I really think holistically, for the country, the proposed rules are going to result in a step backwards on the path to value.
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Value-Based Care Is Key to Bringing Cardiology Breakthroughs to Those Who Will Benefit Most
March 13th 2025On December 10, 2024, cardiologists, researchers, and value-based care experts gathered in Dallas, Texas, to discuss best practices for implementing advances in cardiology care with a value-based mindset, spanning the care continuum from prevention to treatment.
Read More
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More
Late-Breaking Antiviral Session Features Phase 3 Results on Efficacy of Doravirine/Islatravir
March 13th 2025The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who switched to doravirine plus islatravir.
Read More